Biospecifics technologies corp (BSTC)
CashFlow / Yearly
Dec'19Dec'18Dec'17Dec'16Dec'15Dec'14Dec'13Dec'12Dec'11Dec'10Dec'09
Cash flows from operating activities:
Net income

24,469

20,053

11,328

11,372

9,617

4,645

5,285

2,981

6,601

-1,508

-1,956

Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation and amortization

314

2,432

2,239

1,691

933

247

64

64

50

18

35

Stock-based compensation expense

861

263

127

133

105

21

111

228

517

1,901

1,490

Deferred tax expense (credit)

-175

-90

-1,550

2,667

-455

-429

10

-1,474

3,047

0

0

The amount of accrued liabilities extinguished.

0

78

0

0

-

-

-

-

-

-

-

Amount of non-cash operating lease expense during the period.

3

0

-

-

-

-

-

-

-

-

-

Gain on the sale of fixed assets

-

-

-

-

-

1

0

0

-

-

-

Changes in operating assets and liabilities:
Accounts receivable

2,547

4,308

844

1,262

-390

-2,051

-77

1,845

1,250

459

-5,616

Income tax payable

-356

763

-563

-422

263

397

204

-193

-

-

-

Prepaid expenses and other current assets

319

23

-0

240

124

-81

176

51

65

28

371

Patent costs

226

121

204

23

25

198

0

154

-

-

-

Accounts payable and accrued expenses

-802

325

195

127

67

-90

121

-88

-3,009

24

55

Deferred royalty buy-down

-

-

600

600

600

600

600

1,500

-

-

-

Deferred revenue

0

-139

-1,198

7,398

-

-

-

-

-

-

-

Deferred revenue

-

-

-

-

50

-59

-133

-372

-483

-831

-1,145

Net cash provided by operating activities

-

-

-

-

-

6,129

4,535

930

-

-

-

Net cash provided by operating activities

22,285

17,730

13,157

16,352

10,606

-

-

-

-687

-882

3,724

Cash flows from investing activities:
Maturities of marketable investments

93,068

75,170

54,320

43,242

14,070

7,646

9,710

5,070

5,360

4,548

2,799

Purchases of marketable investments

125,102

86,629

64,687

59,935

34,180

12,848

11,556

5,190

5,000

5,360

6,448

Proceeds from sale of fixed assets

-

-

-

-

-

1

0

0

-

-

-

Net cash provided by (used in) investing activities

-

-

-

-

-

-5,200

-1,846

-120

-

-

-

Payment for royalty buy down

-

-

-

-

-

-

-

-

0

0

-

Net cash provided by (used in) investing activities

-32,033

-11,458

-10,366

-16,692

-20,109

-

-

-

360

-812

-3,648

Cash flows from financing activities:
Proceeds from stock option exercises

2,191

2,570

395

711

2,823

2,146

30

148

82

673

380

Payments for repurchase of common stock

620

3,000

616

1,048

1,802

829

674

1,034

739

458

0

Excess tax benefits from share-based payment arrangements

-

-

0

302

3,808

1,939

197

262

1,709

0

0

Net cash provided by (used in) financing activities

-

-

-

-

-

3,257

-447

-623

-

-

-

Net cash (used in) provided by financing activities

1,571

-429

-220

-34

4,829

-

-

-

1,052

215

380

Increase in cash and cash equivalents

-8,177

5,842

-

-

-

-

-

-

-

-

-

Increase (decrease) in cash and cash equivalents

-

-

2,570

-374

-4,672

4,185

2,241

186

725

-1,479

456

Supplemental disclosures of cash flow information:
Amount of recognition of right of use asset and related lease obligations during the period.

242

0

-

-

-

-

-

-

-

-

-

Cash paid during the year for [Abstract]
Interest

0

0

0

0

0

-

-

-

-

-

-

Taxes

5,292

5,417

5,400

7,945

1,906

-

-

-

-

-

-

Interest

-

-

-

-

-

0

0

0

0

0

0

Taxes

-

-

-

-

-

415

2,713

232

190

9

-214